7 active not recruiting, 1 completed, 1 terminated, 1 withdrawn. 7 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 5, Completed 1, Withdrawn 1 |
| Phase 1 | 6 | Active not recruiting 5, Terminated 1 |
Follow Copanlisib Hydrochloride: new trials by email Literature Review of Copanlisib Hydrochloride trials Research Report on Copanlisib Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Copanlisib Hydrochloride, Venetoclax - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 8 | 2022-06-29 | 2026-04-20 |
| Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2021-03-01 | 2026-07-31 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2020-07-17 | 2026-06-17 |
| Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer Abemaciclib, Biopsy Procedure, Biospecimen Collection - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2020-06-17 | 2026-09-08 |
| Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma Copanlisib Hydrochloride, Nivolumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2019-12-13 | 2025-03-03 |
| Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 39 | 2019-11-21 | 2026-09-29 |
| Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2018-06-20 | 2026-05-05 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-22 |
Breast Neoplasms (3) · Lymphoma (2) · Multiple Myeloma (2) · Neoplasm Metastasis (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Lung Neoplasms (1) · Lymphoma, B-Cell, Marginal Zone (1)
National Cancer Institute (NCI) (8) · City of Hope Medical Center (1) · Mayo Clinic (1)
United States (10) · Canada (1) · Guam (1) · Puerto Rico (1)
Timothy A Yap (2) · Alexey Danilov (1) · Cynthia X Ma (1) · Grzegorz S. Nowakowski, M.D. (1) · Keith T Flaherty (1) · Nabila N Bennani (1) · Nusayba Bagegni (1) · Panagiotis A Konstantinopoulos (1) · Senthilkumar Damodaran (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729
U10CA180820 (2), U24CA196172 (2), UM1CA186688 (2), UM1CA186689 (2), UM1CA186704 (2), P30CA033572 (1), U10CA180868 (1), UM1CA186686 (1), UM1CA186709 (1)